ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      Current Value of Holding

      $0

      Shares

      0

      % of Portfolio

      0.00%

      Average Buy Price

      $47.7

      Avg closing price
      Price range

      5 Paul Tudor Jones II Sanofi Trades

      The first Sanofi trade was made in Q1 2015. Since then Paul Tudor Jones II bought shares two more times and sold shares on two occasions. The investor sold all their shares in Q2 2016 and doesn't own any shares in Sanofi anymore.

      Avg closing price
      Price range
      Sold -8.26k shares Q2 2016
      Avg closing price $41.00
      Price range $38.13 - $44.32
      Increased shares by 42.2% (+2.45k shares) Q1 2016
      Avg closing price $40.18
      Price range $38.37 - $42.25
      New holding (+5.81k shares) Q3 2015
      Avg closing price $50.92
      Price range $46.64 - $54.98
      Sold -7.6k shares Q2 2015
      Avg closing price $50.68
      Price range $48.81 - $52.35
      New holding (+7.6k shares) Q1 2015
      Avg closing price $47.81
      Price range $44.00 - $51.12

      News about Sanofi - ADR and Paul Tudor Jones II

      Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A

      Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A

      NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A ALTUVIII...

      globenewswire.com globenewswire.com, about 1 year ago
      Hot Stocks: Brokerage view on Paytm, Havells, Sanofi and TCS

      Hot Stocks: Brokerage view on Paytm, Havells, Sanofi and TCS

      IIFL downgraded Sanofi India to Reduce from ADD earlier with a target price of Rs 8,125. The stock continues to underperform domestic market growth. New laun...

      Economic Times India Economic Times India, over 1 year ago
      Sanofi - Aventis Groupe: Press Release: Once-weekly ALTUVIIIO? approved in Japan as a new class of factor VIII therapy for hemophilia A

      Sanofi - Aventis Groupe: Press Release: Once-weekly ALTUVIIIO? approved in Japan as a new class of factor VIII therapy for hemophilia A

      Once-weekly ALTUVIIIO? approved in Japan as a new class of factor VIII therapy for hemophilia A ALTUVIIIO is a first-in-class, high-sustained factor VIII rep...

      Finanz Nachrichten Finanz Nachrichten, almost 2 years ago
      Sanofi - Aventis Groupe: Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing

      Sanofi - Aventis Groupe: Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing

      ALTUVIIIOTM late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing XTEND-Kids...

      Finanz Nachrichten Finanz Nachrichten, about 2 years ago

      Embed chart

      Easily embed the chart on your blog or website ¨C it will always update automatically!

      HoMEÔçÒÒŮѸÀ×